MARIE CHARLES: Open Payments
NPI 1447407507 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,882 in 50 payments from 11 companies in 2025. Trend: 2023 $1,162 · 2024 $4,358 · 2025 $2,882
Food & beverage: $2,882
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $690 |
| E.R. Squibb & Sons, L.L.C. | 6 | $565 |
| Janssen Pharmaceuticals, Inc | 5 | $350 |
| Alkermes, Inc. | 5 | $331 |
| Luye Pharma (USA) Ltd. | 8 | $281 |
| Teva Pharmaceuticals USA, Inc. | 4 | $177 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
| Gilead Sciences, Inc. | 1 | $119 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
Products named: INGREZZA, COBENFY, ERZOFRI EXTENDED-RELEASE, ARISTADA, INVEGA SUSTENNA, UZEDY, SPRAVATO, VOQUEZNA.
Industry payments across NY — which companies pay providers there.
